12:00 AM
 | 
Feb 01, 2016
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lifitegrast regulatory update

Shire resubmitted an NDA to FDA for lifitegrast to treat signs and symptoms of dry eye disease in adults. In October, the company received...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >